{
    "Trade/Device Name(s)": [
        "BinaxNOW\u00ae G6PD Test",
        "BinaxNOW\u00ae G6PD"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K161364",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080003"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JBF"
    ],
    "Summary Letter Date": "May 17, 2016",
    "Summary Letter Received Date": "May 18, 2016",
    "Submission Date": "June 13, 2016",
    "Regulation Number(s)": [
        "21 CFR 864.7360"
    ],
    "Regulation Name(s)": [
        "Erythrocytic glucose-6-phosphate dehydrogenase assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "Glucose-6-Phosphate Dehydrogenase (G6PD)"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme chromatographic test",
        "Lateral flow assay",
        "Visual determination"
    ],
    "Methodologies": [
        "Qualitative enzyme activity detection",
        "Chromatography",
        "Colorimetric screening"
    ],
    "Submission Type(s)": [
        "Test",
        "Screening Test",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for BinaxNOW\u00ae G6PD enzyme chromatographic lateral flow visual screening test for G6PD activity in whole blood",
    "Indications for Use Summary": "Qualitative visual screening test to detect G6PD enzyme activity in human venous whole blood (heparin or EDTA), aiding identification of individuals with G6PD deficiency; deficient samples should be verified by a quantitative G6PD test method",
    "fda_folder": "Hematology"
}